New blood test could detect heart attacks more quickly

A new blood test can detect heart attacks hours faster than the current gold-standard blood test, according to a study led by Loyola University Chicago Stritch School of Medicine researchers.

The new test measures a protein that is released to the bloodstream by dying heart muscle. The protein is called cardiac myosin binding protein-C (cMyBP-C). The study found that cMyBP-C is released to the blood within just 15 minutes of cardiac damage, and rises to significant levels in three hours.

"This is a potential ultra-early biomarker that could confirm whether a patient has had a heart attack, leading to faster and more effective treatment," said Sakthivel Sadayappan, PhD, senior author of the study, published in the American Journal of Physiology – Heart and Circulatory Physiology.

Between 60 and 70 percent of all patients who complain of chest pain do not have heart attacks. Many of these patients are admitted to the hospital, at considerable time and expense, until a heart attack is definitively ruled out.

An electrocardiogram can diagnose major heart attacks, but not minor ones. There also are blood tests for various proteins associated with heart attacks. But most of these proteins are not specific to the heart. Elevated levels could indicate a problem other than a heart attack, such as a muscle injury.

The only protein now used in blood tests that is specific to the heart is called cardiac troponin-I. It's the gold standard for detecting heart attacks. But it takes at least four to six hours for this protein to show up in the blood following a heart attack. So the search is on for another heart attack protein that is specific to the heart.

Like troponin-I , cMyBP-C is a protein specific to the heart. But it is more readily detected because of its large molecular size and relatively high concentration in the blood. During a heart attack, a is blocked, and heart muscle cells begin to die due to lack of blood flow and oxygen. As heart cells die, cMyBP-C breaks into fragments and is released into the .

Sadayappan and colleagues found that cMyBP-C levels in a group of 176 were more than 18 times higher than cMyBP-C levels in a control group of 153 patients who did not have heart attacks. In a separate analysis of 12 cardiac patients who underwent a procedure that mimicked a minor heart attack, researchers found that cMyBP-C levels peaked four hours after the procedure. Researchers found similar results in a porcine model of heart attack.

"These findings suggest that cMyBP-C has potential as an ultra-early biomarker for the diagnosis of [], but this still needs to be validated using a large cohort study," Sadayappan and colleagues wrote. A cMyBP-C "might lead to an earlier diagnosis in patients who present at the emergency department shortly after coronary artery blockage. However, a systemic prospective investigation is required to establish such data for clinical use."

add to favorites email to friend print save as pdf

Related Stories

Potential new heart attack biomarker uncovered

Dec 10, 2009

Though they remain a leading killer, heart attacks can be effectively treated provided they can be rapidly diagnosed following initial onset of symptoms. In a study appearing in this month's Molecular and Cellular Proteomics, resear ...

Chest pain duration can signal heart attack

Sep 11, 2013

Patients with longer-lasting chest pain are more likely having a heart attack than those with pain of a shorter duration, according to a study by researchers at Henry Ford Hospital.

Recommended for you

Time to take notice and tackle heart failure

9 hours ago

Experts have sounded a call to action for policy makers at local, national, and international levels to promote heart failure prevention, improve heart failure awareness among healthcare professionals, ensure ...

Hopes dashed for an agent to prevent reperfusion injury

12 hours ago

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective ...

User comments